circ-RAD18 was found to be highly expressed in patients with AML, promotes AML cell proliferation, and accelerates tumor progression via miR-206/protein kinase CAMP-activated catalytic subunit beta (PRKACB) (44). Here, PRKACB is linked to acute myeloid leukemia.